Stock listing
NASDAQ:CALC CalciMedica, Inc. Stock
Home listing (NASDAQ) of CalciMedica, Inc.
Follow CalciMedica, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CALC
$1.26 USD +0.09 (+7.7%)
Close on Nov 20, 2026
- Day range
- $1.20 – $1.33 USDNov 20, 2026
- Volume
- 86,246 sharesNov 20, 2026
- Market cap
- $8.69M USDAt the close on Nov 20, 2026 · price × 6.90M shares outstanding
- 52-week range
- $1.00 – $36.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $117,397 USDMedian day 55,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CALC · Home | $1.26 USD | +0.09 (+7.7%) | 86,246 | $1.28 | $1.33 | $1.20 | $1.17 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CALC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.26 | +0.09 | +7.7% | $1.28 | $1.33 | $1.20 | 86,246 | |
| $1.17 | -0.05 | -4.1% | $1.19 | $1.22 | $1.15 | 33,644 | |
| $1.22 | +0.03 | +2.5% | $1.21 | $1.29 | $1.19 | 17,320 | |
| $1.19 | -0.02 | -1.7% | $1.27 | $1.30 | $1.13 | 73,317 | |
| $1.21 | -0.01 | -0.8% | $1.31 | $1.31 | $1.19 | 30,708 | |
| $1.22 | -0.02 | -1.6% | $1.289 | $1.402 | $1.18 | 43,019 | |
| $1.24 | -0.13 | -9.5% | $1.38 | $1.51 | $1.24 | 90,177 | |
| $1.37 | -0.145 | -9.6% | $1.52 | $1.52 | $1.37 | 13,159 | |
| $1.515 | +0.155 | +11.4% | $1.39 | $1.61 | $1.39 | 89,532 | |
| $1.36 | +0.06 | +4.6% | $1.28 | $1.36 | $1.27 | 15,208 | |
| $1.30 | -0.045 | -3.3% | $1.40 | $1.40 | $1.16 | 24,025 | |
| $1.345 | -0.125 | -8.5% | $1.44 | $1.44 | $1.33 | 43,697 | |
| $1.47 | +0.07 | +5.0% | $1.40 | $1.53 | $1.38 | 51,081 | |
| $1.40 | -0.06 | -4.1% | $1.74 | $1.75 | $1.34 | 164,948 | |
| $1.46 | -0.29 | -16.6% | $1.79 | $1.84 | $1.44 | 105,100 | |
| $1.75 | +0.09 | +5.4% | $1.83 | $1.83 | $1.53 | 106,400 | |
| $1.66 | +0.35 | +26.7% | $1.40 | $1.67 | $1.355 | 211,500 | |
| $1.31 | +0.01 | +0.8% | $1.26 | $1.35 | $1.26 | 37,200 | |
| $1.30 | +0.07 | +5.7% | $1.26 | $1.50 | $1.25 | 157,600 | |
| $1.23 | +0.08 | +7.0% | $1.19 | $1.35 | $1.16 | 107,900 | |
| $1.15 | 0.00 | 0.0% | $1.26 | $1.31 | $1.13 | 123,400 | |
| $1.15 | +0.085 | +8.0% | $1.10 | $1.20 | $1.07 | 143,600 | |
| $1.065 | +0.045 | +4.4% | $1.03 | $1.10 | $1.02 | 41,900 | |
| $1.02 | -0.02 | -1.9% | $1.03 | $1.083 | $1.00 | 18,100 | |
| $1.04 | -0.04 | -3.7% | $1.05 | $1.215 | $1.04 | 13,500 | |
| $1.08 | +0.01 | +0.9% | $1.08 | $1.152 | $1.05 | 22,500 | |
| $1.07 | -0.05 | -4.5% | $1.10 | $1.20 | $1.03 | 41,200 | |
| $1.12 | -0.085 | -7.1% | $1.22 | $1.23 | $1.085 | 98,800 | |
| $1.205 | -0.065 | -5.1% | $1.27 | $1.275 | $1.19 | 74,900 | |
| $1.27 | -0.03 | -2.3% | $1.299 | $1.34 | $1.27 | 82,100 | |
| $1.30 | -0.18 | -12.2% | $1.46 | $1.50 | $1.30 | 221,300 | |
| $1.48 | -0.01 | -0.7% | $1.485 | $1.49 | $1.46 | 7,700 | |
| $1.49 | -0.05 | -3.2% | $1.53 | $1.61 | $1.42 | 169,100 | |
| $1.54 | -0.06 | -3.8% | $1.625 | $1.625 | $1.53 | 26,600 | |
| $1.60 | -0.05 | -3.0% | $1.64 | $1.70 | $1.58 | 21,700 | |
| $1.65 | +0.03 | +1.9% | $1.62 | $1.709 | $1.60 | 25,800 | |
| $1.62 | +0.01 | +0.6% | $1.67 | $1.67 | $1.60 | 38,600 | |
| $1.61 | -0.07 | -4.2% | $1.70 | $1.70 | $1.58 | 43,100 | |
| $1.68 | -0.07 | -4.0% | $1.75 | $1.75 | $1.62 | 26,600 | |
| $1.75 | +0.01 | +0.6% | $1.73 | $1.765 | $1.62 | 40,800 | |
| $1.74 | -0.05 | -2.8% | $1.81 | $1.81 | $1.71 | 54,200 | |
| $1.79 | -0.08 | -4.3% | $1.87 | $1.885 | $1.76 | 65,400 | |
| $1.87 | +0.01 | +0.5% | $1.93 | $1.979 | $1.76 | 97,000 | |
| $1.86 | -0.06 | -3.1% | $1.95 | $1.955 | $1.86 | 50,400 | |
| $1.92 | -0.05 | -2.5% | $1.98 | $1.998 | $1.92 | 60,200 | |
| $1.97 | -0.01 | -0.5% | $1.97 | $2.035 | $1.92 | 98,700 | |
| $1.98 | 0.00 | 0.0% | $1.995 | $2.06 | $1.94 | 68,500 | |
| $1.98 | -0.02 | -1.0% | $2.00 | $2.042 | $1.94 | 55,000 | |
| $2.00 | +0.02 | +1.0% | $1.97 | $2.02 | $1.87 | 101,300 | |
| $1.98 | -0.14 | -6.6% | $2.085 | $2.15 | $1.96 | 23,200 | |
| $2.12 | -0.175 | -7.6% | $2.22 | $2.29 | $2.07 | 83,300 | |
| $2.295 | +0.275 | +13.6% | $2.03 | $2.31 | $1.91 | 181,600 | |
| $2.02 | -0.15 | -6.9% | $2.11 | $2.15 | $1.992 | 122,600 | |
| $2.17 | -0.03 | -1.4% | $2.13 | $2.25 | $2.09 | 94,100 | |
| $2.20 | +0.10 | +4.8% | $2.115 | $2.27 | $2.115 | 94,600 | |
| $2.10 | +0.10 | +5.0% | $2.02 | $2.215 | $2.02 | 113,600 | |
| $2.00 | -0.14 | -6.5% | $2.11 | $2.26 | $2.00 | 140,300 | |
| $2.14 | -0.18 | -7.8% | $2.30 | $2.473 | $2.13 | 165,100 | |
| $2.32 | -0.03 | -1.3% | $2.33 | $2.38 | $2.20 | 27,032 | |
| $2.35 | -0.59 | -20.1% | $2.65 | $2.75 | $2.335 | 59,620 | |
| $2.94 | 0.00 | 0.0% | $3.00 | $3.00 | $2.865 | 7,088 | |
| $2.94 | +0.16 | +5.8% | $2.755 | $2.945 | $2.735 | 8,748 | |
| $2.78 | -0.085 | -3.0% | $2.90 | $2.995 | $2.75 | 9,968 | |
| $2.865 | -0.05 | -1.7% | $2.965 | $3.00 | $2.805 | 10,864 | |
| $2.915 | -0.15 | -4.9% | $3.08 | $3.15 | $2.85 | 43,500 |
Splits
1 split · NASDAQ:CALC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation |
- Ticker
- NASDAQ:CALC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 26 slides
Latest news
CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Nov 10, 2026
Closed $1.37 (-9.6%) on Nov 10, 2026
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 3, 2026
Closed $1.47 (+5.0%) on Nov 3, 2026
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 8, 2026
Closed $2.02 (-6.9%) on Sep 8, 2026
CalciMedica Announces One-for-Five Reverse Stock Split
Aug 27, 2026
Closed $2.35 (-20.1%) on Aug 27, 2026
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Aug 11, 2026
Closed $3.29 (-0.2%) on Aug 11, 2026
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
Jul 29, 2026
Closed $3.72 (+3.5%) on Jul 29, 2026
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
Jun 24, 2026
Closed $2.99 (-25.7%) on Jun 24, 2026
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
Jun 24, 2026
Closed $2.99 (-25.7%) on Jun 24, 2026
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
May 12, 2026
Closed $3.15 (+6.6%) on May 12, 2026
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Mar 3, 2026
Closed $2.90 (+14.4%) on Mar 3, 2026
CalciMedica, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 58 in all · newest Nov 10, 2026 · oldest 2023
- Decks
- 8 decks · latest November 2026
Where CalciMedica, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CALC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CALC | BOATS | United States | USD |
Valuation
Price/book 2.1× against a median of 1.3×: 5th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.82M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 1.6×
- Beta vs S&P 500
- 0.54
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CalciMedica, Inc. · NASDAQ:CALC | US$8.69M | US$1.82M | n/a | n/a | n/a | 2.1× | n/a | 1.6× | 0.54 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| CytoMed Therapeutics Limited · NASDAQ:GDTC | US$9.01M | US$8.23M | n/a | 14.7× | n/a | 2.3× | −730.3% | 0.1× | 0.16 |
| PreveCeutical Medical Inc · CSE:PREV | US$8.97M | US$8.95M | n/a | n/a | n/a | n/a | n/a | n/a | 0.73 |
| BioLineRX Ltd. · TASE:BLRX | US$8.90M | US$10.13M | n/a | 8.6× | n/a | 0.5× | −171.7% | 0.3× | n/a |
| Active Biotech AB · OMXSTO:ACTI | US$8.66M | US$4.38M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | n/a |
| BioVie Inc. · NASDAQ:BIVI | US$8.58M | US$1.10M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.84 |
| Vyome Holdings, Inc. · NASDAQ:HIND | US$8.42M | US$1.82M | n/a | 11.9× | n/a | 1.3× | n/a | 0.1× | 1.34 |
| CRISM Therapeutics Corporation · LSE:CRTX | US$8.34M | US$5.37M | n/a | 17.8× | n/a | 2.5× | −823.8% | 0.0× | n/a |
| Brainstorm Cell Therapeutics Inc. · OTC:BCLI | US$8.31M | US$10.08M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTM | US$8.29M | −US$3.20M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.05 |
| Median of the others | US$8.62M | US$6.80M | 11.9× | 1.3× | −451.0% | 0.1× | 0.73 |
Forecasts
3 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 38.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.02 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| A. Rachel Leheny | Chief Executive Officer |
| Stephen Bardin | Chief Financial Officer |
| Michael J. Dunn | President & Chief Operating Officer |
| John M. Dunn | General Counsel |
| Stacey Ruiz | Senior Vice President, Clinical Development |
| Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board |
| Kenneth A. Stauderman | Chief Scientific Officer |
| Sudarshan Hebbar | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Bob Wilson | Chairman of the Board |
| A. Rachel Leheny | Chief Executive Officer |
| Alan Glicklich | Director |
| Allan L. Shaw | Director |
| Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board |
| Evgeny Zaytsev | Director |
| Fred Guerard | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −9.6% |
| Q2 2026 | Aug 11, 2026 · Before open | −0.1% |
| Q1 2026 | May 12, 2026 · Before open | +6.6% |
| Q4 2025 | Mar 3, 2026 | +23.1% |
| Q3 2025 | Nov 12, 2025 · Before open | +4.0% |
| Q2 2025 | Aug 12, 2025 · Before open | −10.1% |
| Q1 2025 | May 14, 2025 · Before open | −0.9% |
| Q4 2024 | Mar 26, 2025 · Before open | −2.9% |
| Q3 2024 | Nov 13, 2024 · Before open | −2.6% |
| Q2 2024 | Aug 12, 2024 · After close | −3.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | +6.7% |
| Q4 2023 | Mar 28, 2024 · Before open | −0.7% |
| Q3 2023 | Nov 9, 2023 · After close | +7.1% |
| Q2 2023 | Aug 10, 2023 · After close | −0.4% |
| Q1 2023 | May 12, 2023 · After close | −0.4% |
| Q4 2022 | Mar 9, 2023 · Before open | −6.8% |
| Q3 2022 | Nov 10, 2022 · After close | −3.0% |
| Q2 2022 | Aug 11, 2022 · Before open | −1.0% |
| Q1 2022 | May 10, 2022 · After close | −6.8% |
| Q4 2021 | Mar 10, 2022 · Before open | −3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 26 slides | November 2026 |
| Investor Presentation (June 2026) | Investor deck | 29 slides | Jun 24, 2026 |
| Investor Presentation (October 2024) | Investor deck | 38 slides | Oct 30, 2024 |
| American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting | Conference | 13 slides | October 2024 |
| Technical Presentation (June 2024) | Technical | 14 slides | Jun 27, 2024 |
| Investor Presentation (February 2024) | Investor deck | 31 slides | Feb 13, 2024 |
| Investor Presentation (June 2023) | Investor deck | 29 slides | Jun 15, 2023 |
| Merger or Acquisition (November 2022) | Merger or acquisition | 23 slides | Nov 22, 2022 |
Financings
| Raise | Date |
|---|---|
| Private placement of units of common stock or pre-funded warrants with Series A and Series B warrant rights Announced: US$15M–US$49M · US$0.8033 a unit · a right to receive one Series A warrant exercisable at $0.8033 per share and one… · Guggenheim Securities, LLC Dealers: Guggenheim Securities, LLC (lead) Insiders: Members of the Board of Directors and management team participate, priced at or above the Nasdaq Consolidated Closing Bid Price as of June 23, 2026 Use of proceeds: Pulmonary hypertension program: Phase 1b study of Auxora in PAH, IND-enabling work for CM5480, and general corporate purposes | Jun 24, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as GRAYBUG VISION, INC. Priced at US$16.00 a share on Sep 24, 2020.
- Price
- US$16.00 a share
- Shares offered
- 5,625,000 shares of common stock
- Offering size
- US$90 million
- Underwriters' option
- Up to 843,750 more shares
- Underwriters
- SVB Leerink, Piper Sandler, Needham & Company, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Sep 29, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 31, 2020 |
| Filed publicly | Sep 4, 2020 |
| Amended once | Sep 21, 2020 |
| Shares registered with an exchange | Sep 21, 2020 |
| Declared effective by the SEC | Sep 24, 2020 |
| Final prospectus, with the price | Sep 25, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 25, 2020 |
| EFFECT · Notice that a registration is effective | Sep 24, 2020 |
| S-1MEF · Registration of more shares for the same offering | Sep 24, 2020 |
| CERT · Exchange's certificate of listing | Sep 24, 2020 |
| CORRESP · Letter to the SEC | Sep 22, 2020 |
| CORRESP · Letter to the SEC | Sep 22, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 21, 2020 |
| S-1/A · Registration statement, amended | Sep 21, 2020 |
| CORRESP · Letter to the SEC | Sep 8, 2020 |
| CORRESP · Letter to the SEC | Sep 4, 2020 |
All 13 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Sep 4, 2020 |
| UPLOAD · Letter from the SEC | Aug 28, 2020 |
| DRS · Draft registration statement | Jul 31, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 25, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 46.0K | 58.0K | 58.0K | 52.0K | 519.0K | 395.0K | 303.0K | 175.0K |
| Gross profit | -46.0K | -58.0K | -58.0K | -52.0K | -519.0K | -395.0K | -303.0K | -175.0K |
| Research and development | 15.2M | 14.5M | 15.9M | 8.35M | 18.9M | 21.0M | 30.6M | 23.0M |
| Selling, general and administrative | 7.89M | 9.73M | 22.2M | 5.84M | 17.0M | 8.87M | 6.92M | 5.60M |
| Operating income | -23.1M | -24.2M | -38.1M | -14.2M | -35.9M | -29.8M | -37.5M | -28.6M |
| Depreciation and amortization | 46.0K | 58.0K | 58.0K | 52.0K | 519.0K | 395.0K | 303.0K | 175.0K |
| EBITDA | -23.1M | -24.1M | -38.0M | -14.1M | -35.4M | -29.4M | -37.2M | -28.4M |
| Interest expense | 1.42M | 0 | 110.0K | 132.0K | 126.0K | 143.0K | ||
| Income before tax | -29.6M | -13.7M | -34.4M | -7.82M | -35.8M | -27.5M | -37.0M | -28.4M |
| Income tax | 0 | 0 | 1.00K | 1.00K | -2.00M | -538.0K | -393.0K | 13.9K |
| Net income | -29.6M | -13.7M | -34.4M | -7.82M | -35.8M | -27.5M | -37.0M | -28.4M |
| Earnings per share, basic | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | -5.25 | -33.41 | -165.51 |
| Earnings per share, diluted | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | -5.25 | -33.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 11.5M | 7.93M | 5.53M | 1.33M | 13.4M | 33.4M | 15.9M | 12.8M |
| Short-term investments | 1.50M | 10.7M | 5.71M | 0 | 50.3M | 61.6M | 20.1M | |
| Receivables | 39.0K | 21.0K | ||||||
| Inventory | -39.0K | -21.0K | ||||||
| Current assets | 13.5M | 19.7M | 11.6M | 1.73M | 67.1M | 99.2M | 36.3M | 13.4M |
| Property, plant and equipment | 50.0K | 119.0K | 167.0K | 147.0K | 1.98M | 1.95M | 1.98M | |
| Total assets | 13.6M | 19.8M | 12.2M | 3.35M | 69.1M | 101.8M | 40.7M | 17.8M |
| Accounts payable | 1.16M | 2.00M | 1.42M | 2.87M | 527.0K | 2.51M | 4.64M | 2.52M |
| Current liabilities | 3.78M | 3.68M | 4.03M | 4.78M | 4.06M | 7.00M | 12.3M | 5.79M |
| Long-term debt | 8.45M | 5.16M | ||||||
| Total debt | 9.70M | 5.36M | 131.4M | 78.8M | ||||
| Total liabilities | 20.2M | 5.38M | 4.03M | 12.6M | 4.07M | 7.01M | 12.3M | 5.79M |
| Shareholders' equity | -6.64M | 14.4M | 8.16M | -71.3M | -64.0M | 94.8M | -103.0M | 12.0M |
| Shares outstanding | 3.09M | 13.5M | 5.75M | 84.2K | 21.4M | 21.0M | 1.37M | 171.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21.2M | -21.1M | -25.7M | -11.8M | -31.5M | -32.1M | -31.2M | -28.2M |
| Capital spending | -28.0K | -8.00K | -78.0K | -4.00K | -488.0K | -1.02M | -605.0K | -1.46M |
| Free cash flow | -21.2M | -21.2M | -25.8M | -11.8M | -32.0M | -33.1M | -31.8M | -29.7M |
| Cash from investing | 9.55M | -4.42M | 8.88M | -4.00K | 10.8M | -42.6M | -20.6M | -1.46M |
| Cash from financing | 15.2M | 28.0M | 20.9M | 8.48M | 695.0K | 92.2M | 54.9M | 42.0M |
| Share buybacks | -45.0K | |||||||
| Change in cash | 3.58M | 2.40M | 4.05M | -3.29M | -20.1M | 17.5M | 3.04M | 12.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 16, 2026 | Management or board change | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 424B5 · Prospectus | Sep 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 23, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 8-K · Current report | Sep 2, 2026 | Current report | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 25, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 19, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 3, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jul 24, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Jul 23, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 23, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 13, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Jul 10, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Jul 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 7, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Jul 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 25, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 24, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 24, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 20, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 12, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 9, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 3, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 1, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| S-8 POS | Jun 27, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 24, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Jun 9, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 6, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 28, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 1, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 8-K · Current report | Mar 5, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 3, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Nov 26, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 15, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Nov 8, 2024 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Nov 6, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 31, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 31, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Oct 30, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| 8-K · Current report | Oct 30, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 27, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 27, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
This page holds 200 of 539 filings. Open Filings
Cap table
Built by 6ix from CalciMedica, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 6,895,149
- Fully diluted
- 6,895,149
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,895,149 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 6,895,149 |
| Sep 30, 2026 | 6,894,649 |
| Aug 27, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Fred A Middleton Other companies: Chimerix Inc (Director · Mar 28, 2018 – Apr 21, 2025 · Past); Stereotaxis, Inc. (Director · Jan 3, 2012 – Mar 2, 2018 · Past); Endocyte Inc (Director · Dec 16, 2011 – Dec 21, 2018 · Past); Pacira BioSciences, Inc. (Director · Nov 21, 2011 – Jun 21, 2013 · Past) | Director · Since at least Mar 20, 2023 |
| Julia Marie Eastland Other companies: Zentalis Pharmaceuticals, Inc. (CEO & President, Director · Since at least Nov 13, 2024); Lantheus Holdings, Inc. (Director · Since at least Sep 3, 2024); Dynavax Technologies Corporation (Director · May 28, 2021 – May 23, 2024 · Past); Harpoon Therapeutics Inc (President and CEO, Director · May 4, 2021 – Mar 11, 2024 · Past) | Director · Jun 2, 2021 – Mar 23, 2023 · Past |
| Robert N Wilson Other companies: VIVUS Inc (Director · Apr 26, 2013 – Aug 14, 2013 · Past); Madrigal Pharmaceuticals, Inc. (Director · Feb 5, 2007 – Jul 1, 2015 · Past); Hess Corporation (Director · Jan 30, 2006 – Mar 1, 2016 · Past); Charles Schwab Corporation (the) (Director · Jan 3, 2006 – Dec 13, 2018 · Past) | Director · Since at least Mar 20, 2023 |
| Allan Shaw Other companies: Onconetix, Inc. (Director · Feb 17, 2022 – Aug 19, 2022 · Past); VIVUS Inc (Director · Oct 15, 2017 – Oct 26, 2018 · Past) | Director · Since at least Mar 20, 2023 |
| Christy L Shaffer Other companies: G1 Therapeutics Inc (Director · May 16, 2017 – Nov 30, 2017 · Past); Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 20, 2024 · Past) | Director · Sep 24, 2020 – Mar 23, 2023 · Past |
| Eric W. Roberts Other companies: VIVUS Inc (Director · Sep 15, 2015 – Feb 28, 2019 · Past); Invuity Inc (Director · Jun 11, 2015 – Oct 23, 2018 · Past) | Chief Business Officer & Vice Chairman of the Board · Since at least Mar 20, 2023 |
| Gerald D Cagle Other companies: Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 25, 2018 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – Jun 17, 2021 · Past) | Director · Sep 24, 2020 – Jun 2, 2021 · Past |
| Alan Glicklich Other companies: Aduro Biotech Inc (Chief Medical Officer · Oct 5, 2020 – Feb 10, 2022 · Past) | Director · Since at least Jan 14, 2025 |
| A. Rachel Leheny Other companies: Anthera Pharmaceuticals Inc (Director · Feb 23, 2010 – Sep 30, 2010 · Past) | Chief Executive Officer · Since at least Mar 20, 2023 |
| Daniel Salain Other companies: Aceragen Inc. (CHIEF OPERATING OFFICER · Sep 28, 2022 – Jan 20, 2023 · Past) | CTOO · Sep 24, 2020 – Dec 8, 2020 · Past |
All 22 people
| Person | Seat |
|---|---|
| Hansoo Michael Keyoung Other companies: Kairos Pharma, Ltd. (Director · Since at least Sep 16, 2024) | Director · Sep 24, 2020 – Sep 29, 2020 · Past |
| Allan L. Shaw | Director · Since at least Nov 4, 2026 |
| Bob Wilson | Chairman of the Board · Since at least Jun 29, 2026 |
| Dirk Sauer | Director · Apr 13, 2022 – Mar 23, 2023 · Past |
| Evgeny Zaytsev | Director · Since at least Nov 5, 2026 |
| Fred Guerard | Director · Since at least Nov 4, 2026 |
| John M. Dunn | General Counsel · Since at least Nov 4, 2026 |
| Kenneth A. Stauderman | Chief Scientific Officer · Since at least Nov 12, 2025 |
| Michael J. Dunn | President & Chief Operating Officer · Since at least Mar 20, 2023 |
| Stacey Ruiz | Senior Vice President, Clinical Development · Since at least Nov 4, 2026 |
| Stephen Bardin | Chief Financial Officer · Since at least Nov 7, 2024 |
| Sudarshan Hebbar | Chief Medical Officer · Since at least Jun 25, 2026 |
Log in to ask 6ix AI your own questions about CalciMedica, Inc.